Technology

Learn more about Hexima’s technology.
 

HXP124

Hexima is conducting a phase I/IIa clinical trial of its lead antifungal molecule, HXP124, as a treatment for fungal nail infections.

Latest news

Mr Scott Robertson appointed to Board of Directors

Hexima Limited has announced the appointment of Mr Scott Robertson to its Board of Directors, effective 21 November 2018. Speaking at Hexima’s recent AGM, Chairman Professor Jonathan West said “I am pleased to announce today that we will be adding Mr Scott Robertson...

AGM 2018 – Presentation and Results

Presentations and Results from the 2018 Hexima Limited Annual General Meeting held 20 November 2018. AGM 2018 Chairman’s Address AGM 2018 CEO & CSO Presentation AGM 2018 Meeting...

Chairman and CEO update

It is our pleasure to report on an exciting year at Hexima, during which we progressed our lead drug candidate, HXP124, into first-in-human clinical trials. This is a pivotal step in the development of HXP124 as a safe and effective treatment for fungal nail...

External Links

Take a look at these useful links to learn more about our industry.

Australian Academy of Science
Australian Science Media Centre logo